Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Innoviva Specialty Therapeutics has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in South and Central America, the Caribbean, Russia, and CIS countries. Dr. Reddy’s will oversee development, regulatory, and commercialization activities in the licensed territory, while Innoviva retains rights elsewhere and is eligible for upfront payments, milestones, and royalties.
Key figures
- Patient age threshold
- 18 years
- Carbapenem resistance rate
- 70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.